Becker's Hospital Review

FDA partially pauses cancer drug trial after patient death

The FDA has placed a partial clinical hold on a cancer drug trial following four safety events, including one death, according to a Feb. 25 announcement from MacroGenics.  The partial hold pauses ...

CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Encouraging Results from Phase 2 HIT Trial On February 24, 2026, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced encouraging results from ...
CURE

FDA Pauses Lorigerlimab Study in Gynecologic Cancers After Patient Death

The FDA placed a partial hold on a phase 2 lorigerlimab trial in gynecologic cancers after a patient died from grade 4 ...
BioSpace

Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study

A patient has died in a mid-stage study of MacroGenics’ bispecific antibody lorigerlimab in gynecologic cancers, prompting ...